NCT01353079

Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy

Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy And Safety Trial Of Sublingual-Oral Immunotherapy (SLIT) In Adults With Allergic Rhinoconjunctivitis Caused By Ragweed Pollen

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 429 (actual)
• Sponsor: Greer Laboratories · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to demonstrate that SLIT administered pre-and co-seasonally is effective in reducing rhinoconjunctivitis symptoms during the entire short ragweed pollen season.

Conditions

• Allergy

Interventions

Type	Name	Description
BIOLOGICAL	Short Ragweed Pollen Allergenic Extract	Daily sublingual administration of Short Ragweed Pollen Allergenic Extract up to 42 U Amb a 1 for a minimum of 8 weeks prior to the ragweed pollen season.
BIOLOGICAL	Placebo	Placebo: Glycero-COCAs sublingual

Timeline

• Start date: 2011-04-01
• Primary completion: 2011-11-01
• Completion: 2012-04-01
• First posted: 2011-05-12
• Last updated: 2015-02-05
• Results posted: 2015-02-05

Locations

1 site across 1 country: United States